Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

1.370 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Unusual volume stocks in Thursday's session ↗

July 02, 2026

Via Chartmill

Wondering what's happening in today's after-hours session? ↗

July 01, 2026

Via Chartmill

What's going on in today's pre-market session ↗

July 01, 2026

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 30, 2026

Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ:VVOS) shares...

Via Benzinga

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants ↗

November 19, 2025

Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.

Via Benzinga

Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 21, 2025

Via Benzinga

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

July 28, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

July 23, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

June 16, 2025

Capital Raised to Support Five Clinical Trials

From Alzamend Neuro, Inc.

Via GlobeNewswire

Which stocks are experiencing notable movement on Friday? ↗

May 30, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 30, 2025

Via Benzinga

Top movers in Friday's session ↗

May 30, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Traders are paying attention to the gapping stocks in Friday's session. ↗

May 30, 2025

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Synergy CHC Corp. (NASDAQ: SNYR) Taps Beverage Veteran to Drive FOCUSfactor’s Drink Expansion – More Stocks Inside

May 29, 2025

Via AB Newswire

Topics Economy

Let's take a look at the stocks that are in motion in today's session. ↗

May 29, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled ↗

May 29, 2025

AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.

Via Stocktwits

Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone ↗

May 29, 2025

Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims for improved brain delivery and fewer side effects.

Via Benzinga

Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results ↗

May 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 29, 2025

Via Benzinga

Keep an eye on the top gainers and losers in Thursday's session. ↗

May 29, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

The market is filled with gapping stocks in Thursday's session. ↗

May 29, 2025

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs

May 29, 2025

Via Investor Brand Network

Topics Artificial Intelligence

Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue ↗

May 29, 2025

Via Benzinga

BioMedNewsBreaks — Alzamend Neuro, Inc. (NASDAQ: ALZN) Doses First Patient in Phase II Trial for Next-Gen Lithium Therapy AL001

May 29, 2025

Via Investor Brand Network

What's going on in today's pre-market session ↗

May 29, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 29, 2025

Via Benzinga

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 29, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 19, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Which stocks are moving before the opening bell on Tuesday? ↗

May 13, 2025

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 13, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.